Sildenafil delays bone remodeling of fractured femora in aged mice by reducing the number and activity of osteoclasts within the callus tissue

Biomed Pharmacother. 2024 Apr:173:116291. doi: 10.1016/j.biopha.2024.116291. Epub 2024 Mar 4.

Abstract

The elderly exhibit a reduced healing capacity after fracture, which is often associated with delayed or failed bone healing. This is due to a plethora of factors, such as an impaired bone vascular system and delayed angiogenesis. The phosphodiesterase-5 (PDE-5) inhibitor sildenafil exerts pro-angiogenic and pro-osteogenic effects. Hence, we herein investigated in aged mice whether sildenafil can improve fracture healing. For this purpose, 40 aged CD-1 mice (16-18 months) were daily treated with 5 mg/kg body weight sildenafil (n = 20) or vehicle (control, n = 20) by oral gavage. The callus tissue of their femora was analyzed at 2 and 5 weeks after fracture by X-ray, biomechanics, micro-computed tomography (µCT), histology, immunohistochemistry as well as Western blotting. These analyses revealed a significantly increased bone volume and higher ratio of callus to femoral bone diameter in sildenafil-treated mice at 5 weeks after fracture when compared to controls. This was associated with a reduced number and activity of osteoclasts at 2 weeks after fracture, most likely caused by an increased expression of osteoprotegerin (OPG). Taken together, these findings indicate that sildenafil does not improve fracture healing in the elderly but delays the process of bone remodeling most likely by reducing the number and activity of osteoclasts within the callus tissue.

Keywords: Aging; Angiogenesis; Fracture healing; Mice; OPG; Sildenafil.

MeSH terms

  • Aged
  • Animals
  • Bone Remodeling
  • Femoral Fractures* / diagnostic imaging
  • Femoral Fractures* / drug therapy
  • Fracture Healing
  • Humans
  • Mice
  • Osteoclasts*
  • Phosphodiesterase 5 Inhibitors / pharmacology
  • Sildenafil Citrate / pharmacology
  • Sildenafil Citrate / therapeutic use
  • X-Ray Microtomography

Substances

  • Sildenafil Citrate
  • Phosphodiesterase 5 Inhibitors